Reaseach programme: HDAC6 inhibitor therapeutics - Shuttle Pharmaceuticals
Alternative Names: HDAC inhibitor therapeutics - Shuttle PharmaceuticalsLatest Information Update: 09 Sep 2024
At a glance
- Originator Shuttle Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer
- Research Immunological disorders; Neurological disorders
Most Recent Events
- 03 Sep 2024 Shuttle Pharmaceuticals announces issuance of U.S. Patent titled Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
- 11 Sep 2023 Shuttle Pharmaceuticals receives a issuance of a Canadian patent for its histone deacetylase (HDAC) inhibitor platform
- 15 Sep 2022 Shuttle Pharmaceuticals has patent protection for HDAC6 inhibitors in USA and Hong Kong